Shlevin Harold H. 4

Accession 0001133416-25-000061

CIK 0001133416other

View on SEC.gov Company Profile

Filed

Dec 9, 7:00 PM ET

Accepted

Dec 10, 8:15 AM ET

Size

42.3 KB

Accession

0001133416-25-000061

Insider Transaction Report

Form 4

Period: 2025-12-08

GALECTIN THERAPEUTICS INCGALT

Shlevin Harold H.

Director

Transactions

Sale
Common Stock
2025-12-08$6.00/sh−4,000$24,020→ 11,206 total
Exercise/Conversion
Common Stock
2025-12-08$2.86/sh+35,000$100,100→ 46,206 total
Sale
Common Stock
2025-12-08$5.95/sh−35,000$208,250→ 11,206 total
Exercise/Conversion
Common Stock
2025-12-08$2.11/sh+20,000$42,200→ 31,206 total
Sale
Common Stock
2025-12-08$5.96/sh−20,000$119,240→ 11,206 total
Exercise/Conversion
Common stock
2025-12-08$1.98/sh+20,000$39,600→ 31,206 total
Sale
Common stock
2025-12-08$5.96/sh−20,000$119,240→ 11,206 total
Exercise/Conversion
Common Stock
2025-12-08$1.72/sh+25,000$43,000→ 36,206 total
Sale
Common Stock
2025-12-08$5.95/sh−25,000$148,650→ 11,206 total
Exercise/Conversion
Common Stock
2025-12-09$4.16/sh+16,790$69,846→ 27,996 total
Sale
Common Stock
2025-12-09$6.27/sh−16,790$105,206→ 11,206 total
Exercise/Conversion
Stock option (right to buy)
2025-12-08−35,000→ 35,000 total
Exercise: $2.86From: 2021-12-31Exp: 2031-03-25→ Common Stock (35,000 underlying)
Exercise/Conversion
Stock option (right to buy)
2025-12-08−20,000→ 20,000 total
Exercise: $2.11From: 2021-12-31Exp: 2031-03-25→ Common Stock (20,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-12-08−25,000→ 25,000 total
Exercise: $1.72From: 2024-12-31Exp: 2034-01-24→ Common Stock (25,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-12-08−35,000→ 35,000 total
Exercise: $2.11From: 2024-12-31Exp: 2031-03-25→ Common Stock (35,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-12-08−20,000→ 20,000 total
Exercise: $1.11From: 2023-12-31Exp: 2033-01-26→ Common Stock (20,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2025-12-09−16,790→ 73,210 total
Exercise: $4.16From: 2018-12-31Exp: 2028-05-22→ Common Stock (16,790 underlying)

Footnotes (12)

[F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.
[F10]The shares were sold in multiple transactions at prices ranging from $6.00 to $6.08. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
[F11]The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018.
[F12]The shares were sold in multiple transactions at prices ranging from $6.25 to $6.31. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
[F2]The options vested as follows: 25% on each of June 30, 2021, December 31, 2021, June 30, 2022, and December 31, 2022.
[F3]The options vested 100% on December 31, 2021.
[F4]The options vested 100% on December 31, 2022.
[F5]The options vested 100% on December 31, 2024.
[F6]The options vested 100% on December 31, 2023.
[F7]The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
[F8]The shares were sold in multiple transactions at prices ranging from $5.69 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
[F9]The shares were sold in multiple transactions at prices ranging from $5.69 to $6.034. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Documents

1 file

4
form4.xmlPrimary
FORM 4

Issuer

GALECTIN THERAPEUTICS INC

CIK 0001133416

→

Entity typeother

Related Parties

filerCIK 0001557082

Filing Metadata

Form type: 4
Filed: Dec 9, 7:00 PM ET
Accepted: Dec 10, 8:15 AM ET
Size: 42.3 KB

View on SEC.gov